ST-001 trial for stubborn T-cell lymphoma that came back
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 trial tests ST-001, an experimental treatment, for T-cell lymphomas that have returned or did not respond to prior therapy. It aims to find a safe dose and see whether it can shrink or control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these confirmed T-cell lymphoma types: mycosis fungoides, Sézary syndrome, primary cutaneous CD30+ large cell lymphoma, or certain nodal T-cell lymphomas (PTCL NOS, AITL, or follicular T-cell lymphoma.
- Your lymphoma must be relapsed or refractory, meaning it returned after treatment or did not respond to the most recent treatment.
- You need at least one measurable active disease site for the study to track response.
- You must be at least 18 years old, able to do study procedures, and expected to live more than 6 months.
- Your recent treatments must be finished for long enough (usually at least 4 weeks; longer for some chemo types), and you must be recovered from side effects.
- Your organs and blood counts must be in acceptable ranges (blood counts, liver tests, kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
This study tests a new combination therapy with a drug called tazemetostat for people with peripheral T-cell lymphoma that has relapsed (come back) or is refractory (did not respond to previous treatment). The goal is to see if this combination can help control the lymphoma.
This trial tests a new investigational drug (DT-7012) for people with a type of skin lymphoma that hasn't responded to standard treatments. The drug is given as an infusion and aims to boost your immune system to fight the cancer.
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
This trial is testing a combination of two drugs for T-cell lymphoma that has returned after prior treatment. The drugs are belinostat (given as an infusion) plus either azacitidine or pralatrexate. The goal is to see if this combination can help control the lymphoma and for how long.
This phase 1 trial tests an experimental drug called ST-001 nanoFenretinide for people with small cell lung cancer that has returned or not responded to standard chemotherapy. The drug is a newer form of fenretinide, which is related to vitamin A, and may work differently to attack cancer cells.
Hear when a new T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.